$164.66
+0.41
(+0.25%)▲
AbbVie Inc develops and sells prescription drugs in various therapeutic areas, including immunology, oncology, and virology
0.08%
Downside
Day's Volatility :1.71%
Upside
1.64%
23.57%
Downside
52 Weeks Volatility :30.55%
Upside
9.13%
Period | Abbvie Inc | |
---|---|---|
3 Months | 0.58% | |
6 Months | 10.03% | |
1 Year | 2.92% | |
3 Years | 51.23% |
Market Capitalization | 287.8B |
Book Value | $5.87 |
Dividend Share | 5.99 |
Dividend Yield | 3.81% |
Earnings Per Share (EPS) | 2.71 |
PE Ratio | 59.98 |
PEG Ratio | 0.45 |
Wall Street Target Price | 184.49 |
Profit Margin | 8.95% |
Operating Margin TTM | 31.81% |
Return On Assets TTM | 8.07% |
Return On Equity TTM | 35.2% |
Revenue TTM | 54.3B |
Revenue Per Share TTM | 30.72 |
Quarterly Revenue Growth YOY | -5.4% |
Gross Profit TTM | 41.5B |
EBITDA | 26.4B |
Diluted Eps TTM | 2.71 |
Quarterly Earnings Growth YOY | -0.67 |
EPS Estimate Current Year | 11.11 |
EPS Estimate Next Year | 12.19 |
EPS Estimate Current Quarter | 2.77 |
EPS Estimate Next Quarter | 2.5 |
What analysts predicted
Upside of 12.04%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 32.8B | ↑ 16.08% |
Net Income | 5.7B | ↑ 7.12% |
Net Profit Margin | 17.36% | ↓ 1.46% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 33.3B | ↑ 1.57% |
Net Income | 7.9B | ↑ 38.6% |
Net Profit Margin | 23.69% | ↑ 6.33% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 45.8B | ↑ 37.69% |
Net Income | 4.6B | ↓ 41.44% |
Net Profit Margin | 10.08% | ↓ 13.61% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 56.2B | ↑ 22.69% |
Net Income | 11.5B | ↑ 150.04% |
Net Profit Margin | 20.54% | ↑ 10.46% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 58.1B | ↑ 3.3% |
Net Income | 11.8B | ↑ 2.55% |
Net Profit Margin | 20.39% | ↓ 0.15% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 54.3B | ↓ 6.44% |
Net Income | 4.9B | ↓ 58.91% |
Net Profit Margin | 8.95% | ↓ 11.44% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 14.8B | ↑ 1.57% |
Net Income | 3.9B | ↑ 327.38% |
Net Profit Margin | 26.66% | ↑ 20.32% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 15.1B | ↑ 2.09% |
Net Income | 2.5B | ↓ 37.38% |
Net Profit Margin | 16.35% | ↓ 10.31% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.2B | ↓ 19.15% |
Net Income | 239.0M | ↓ 90.34% |
Net Profit Margin | 1.96% | ↓ 14.39% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.9B | ↑ 13.42% |
Net Income | 2.0B | ↑ 746.86% |
Net Profit Margin | 14.6% | ↑ 12.64% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.9B | ↑ 0.45% |
Net Income | 1.8B | ↓ 12.15% |
Net Profit Margin | 12.77% | ↓ 1.83% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 14.3B | ↑ 2.69% |
Net Income | 822.0M | ↓ 53.77% |
Net Profit Margin | 5.75% | ↓ 7.02% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 59.4B | ↓ 16.15% |
Total Liabilities | 67.8B | ↑ 3.21% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 89.1B | ↑ 50.15% |
Total Liabilities | 97.3B | ↑ 43.5% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 150.6B | ↑ 68.96% |
Total Liabilities | 137.5B | ↑ 41.3% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 146.5B | ↓ 2.68% |
Total Liabilities | 131.1B | ↓ 4.64% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 138.8B | ↓ 5.27% |
Total Liabilities | 121.5B | ↓ 7.3% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 134.7B | ↓ 2.95% |
Total Liabilities | 124.3B | ↑ 2.3% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 141.3B | ↓ 1.3% |
Total Liabilities | 125.3B | ↓ 2.49% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 138.8B | ↓ 1.78% |
Total Liabilities | 121.5B | ↓ 3.02% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 134.5B | ↓ 3.07% |
Total Liabilities | 121.2B | ↓ 0.23% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 135.4B | ↑ 0.61% |
Total Liabilities | 122.5B | ↑ 1.01% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 136.2B | ↑ 0.63% |
Total Liabilities | 124.1B | ↑ 1.33% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 134.7B | ↓ 1.11% |
Total Liabilities | 124.3B | ↑ 0.18% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 13.4B | ↑ 34.81% |
Investing Cash Flow | -1.0B | ↑ 267.15% |
Financing Cash Flow | -14.4B | ↑ 161.18% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 13.3B | ↓ 0.77% |
Investing Cash Flow | 596.0M | ↓ 159.24% |
Financing Cash Flow | 18.7B | ↓ 229.95% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 17.6B | ↑ 32.0% |
Investing Cash Flow | -37.6B | ↓ 6401.51% |
Financing Cash Flow | -11.5B | ↓ 161.48% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 22.8B | ↑ 29.5% |
Investing Cash Flow | -2.3B | ↓ 93.76% |
Financing Cash Flow | -19.0B | ↑ 65.54% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 24.9B | ↑ 9.51% |
Investing Cash Flow | -623.0M | ↓ 73.42% |
Financing Cash Flow | -24.8B | ↑ 30.27% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 7.6B | ↑ 51.89% |
Investing Cash Flow | 1.3B | ↑ 889.23% |
Financing Cash Flow | -5.5B | ↑ 105.97% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 7.4B | ↓ 2.29% |
Investing Cash Flow | -448.0M | ↓ 134.84% |
Financing Cash Flow | -9.6B | ↑ 74.59% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.2B | ↓ 43.55% |
Investing Cash Flow | -499.0M | ↑ 11.38% |
Financing Cash Flow | -6.2B | ↓ 35.73% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 6.3B | ↑ 50.7% |
Investing Cash Flow | -341.0M | ↓ 31.66% |
Financing Cash Flow | -3.9B | ↓ 36.69% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 7.6B | ↑ 19.86% |
Investing Cash Flow | -369.0M | ↑ 8.21% |
Financing Cash Flow | -2.7B | ↓ 32.12% |
Sell
Neutral
Buy
Abbvie Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Abbvie Inc | -7.98% | 10.03% | 2.92% | 51.23% | 111.74% |
Eli Lilly And Company | -2.85% | 23.64% | 102.65% | 295.89% | 550.19% |
Johnson & Johnson | -7.65% | -5.21% | -10.09% | -11.01% | 5.27% |
Merck & Co. Inc. | 3.24% | 22.92% | 9.18% | 61.43% | 71.29% |
Pfizer Inc. | -8.3% | -18.5% | -36.83% | -34.7% | -34.79% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Abbvie Inc | 59.98 | 59.98 | 0.45 | 11.11 | 0.35 | 0.08 | 0.04 | 5.87 |
Eli Lilly And Company | 128.31 | 128.31 | 1.43 | 12.51 | 0.48 | 0.12 | 0.01 | 11.98 |
Johnson & Johnson | 27.78 | 27.78 | 0.89 | 10.65 | 0.18 | 0.08 | 0.03 | 28.57 |
Merck & Co. Inc. | 893.29 | 893.29 | 0.1 | 8.56 | 0.01 | 0.03 | 0.02 | 14.85 |
Pfizer Inc. | 69.43 | 69.43 | 0.26 | 2.21 | 0.02 | 0.02 | 0.07 | 15.77 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Abbvie Inc | Buy | $287.8B | 111.74% | 59.98 | 8.95% |
Eli Lilly And Company | Buy | $713.8B | 550.19% | 128.31 | 15.36% |
Johnson & Johnson | Hold | $348.1B | 5.27% | 27.78 | 41.28% |
Merck & Co. Inc. | Buy | $316.8B | 71.29% | 893.29 | 0.61% |
Pfizer Inc. | Buy | $145.5B | -34.79% | 69.43 | 3.62% |
Vanguard Group Inc
BlackRock Inc
State Street Corporation
JPMorgan Chase & Co
Capital Research & Mgmt Co - Division 3
Geode Capital Management, LLC
In the quarter ending March,2024. Abbvie Inc has declared dividend of $1.55
Read MoreAbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
Organization | Abbvie Inc |
Employees | 50000 |
CEO | Mr. Richard A. Gonzalez |
Industry | Health Technology |